Association between 20 serum mirnas and clinicopathological variables in patients with breast cancer

Creative Commons License

YILDIRIM A., DEMİRAY A., Koç A. C., ŞENOL H., YAREN A.

Pamukkale Tıp Dergisi, cilt.16, sa.2, ss.168-178, 2023 (Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 2
  • Basım Tarihi: 2023
  • Doi Numarası: 10.31362/patd.1216451
  • Dergi Adı: Pamukkale Tıp Dergisi
  • Derginin Tarandığı İndeksler: Scopus, Central & Eastern European Academic Source (CEEAS), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.168-178
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Purpose: Determining microRNAs in breast cancer pathogenesis suggests that it may be beneficial for diagnosis and treatment. Materials and methods: Patients serum were collected and microRNAs were isolated. Then microRNAs was converted to cDNA. After that, investigated serum levels of 20 microRNAs (miR-17, miR-21, miR-34a, miR-105, miR-133a, miR-139-5p, miR-141, miR-143, miR-145, miR-155, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-299-5p, miR-365, miR-375, miR-411, miR-452) in 39 patients with invasive breast cancer were analyzed before and after treatment. Results: In the analysis results, it is detected that serum levels of miR-200c, miR-375, miR-34a were markedly higher in the local advanced/metastatic group. MiR-141 levels was lower in patients with positive lymph node involvement, whereas miR-133a levels were higher in the same patient group. miR-105, miR-203, miR-375, miR-145 serum levels were markedly higher in the progesterone receptor negative group, likewise miR-105 levels were high in the estrogen receptor negative group. The high levels of miR-375 and miR-133a were noticeable in human epidermal growth factor receptor-2 positive patients. MiR-143 and miR-145 levels were observed higher in the patient with a ki-67 index >20%. It was found that 2 miRNAs (miR-133a and miR-139-5p) were markedly higher in patients in the luminal B group, which were separated by molecular subgroups. Nine of miRNAs that evaluated (miR-21, miR-34a, miR-105, miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-452) significantly increased and 5 of the miRNAs (miR-145, miR-365, miR-155, miR-143, miR-299-5p) were significantly reduced post-treatment. Conclusion: We think that miRNAs may help in evaluating the follow-up and prognosis of invasive breast cancer.